CLAIMS

1. An injectable preparation comprising a composition comprising a poorly soluble drug, a dispersion medium, and a suspending agent,

the suspending agent containing polyvinylpyrrolidone,

the composition having a viscosity of 40 Pa·s or more in at least one point in the shear rate range of 0.01 to 0.02 s^{-1} and having a viscosity of 0.2 Pa·s or less in at least one point in the shear rate range of 900 to 1,000 s^{-1}, as measured by a rheometer at 5℃, 25℃ or 40℃,

wherein the poorly soluble drug is aripiprazole or a salt thereof, or 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof,

the poorly soluble drug has a mean primary particle diameter of 30 μm or less and is contained in a concentration of 200 to 600 mg/mL, and

the concentration of polyvinylpyrrolidone is 0.1 to 100 mg/mL.

2. An injectable preparation comprising a composition comprising a poorly soluble drug, a dispersion medium, and a suspending agent,

the suspending agent containing polyvinylpyrrolidone,

the composition having a viscosity of 40 Pa·s or more in at least one point in the shear rate range of 0.01 to 0.02 s^{-1} and having a viscosity of 0.2 Pa·s or less in at least one point in the shear rate range of 900 to 1,000 s^{-1}, as measured by a rheometer at 25℃,

wherein the poorly soluble drug is aripiprazole or a salt thereof, or 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof,

the poorly soluble drug has a mean primary particle diameter of 30 μm or less and is contained in a concentration of 200 to 600 mg/mL, and

the concentration of polyvinylpyrrolidone is 0.1 to 100 mg/mL.

3. The injectable preparation according to claim 1 or 2 comprising a composition comprising at least water as a dispersion medium.

4. The injectable preparation according to any one of claims 1 to 3 wherein the suspending agent further contains polyethylene glycol.

5. The injectable preparation according to any one of claims 1 to 3 wherein the suspending agent further contains polyethylene glycol and carboxymethyl cellulose or a salt thereof.

6. The injectable preparation according to any one of claims 1 to 5 wherein K value of polyvinylpyrrolidone is 12 to 30.

7. A gel composition comprising

a poorly soluble drug which is aripiprazole or a salt thereof, or 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof,

water, and

suspending agent,

wherein the suspending agent contains polyvinylpyrrolidone, the poorly soluble drug has a mean primary particle diameter of 0.5 to 30 μm and is contained in a concentration of 200 to 600 mg/mL, and

the concentration of polyvinylpyrrolidone is 0.1 to 100 mg/mL.

8. The composition according to claim 7 wherein the suspending agent further contains polyethylene glycol.

9. The composition according to claim 7 wherein the suspending agent further contains polyethylene glycol and carboxymethyl cellulose or a salt thereof.

10. The composition according to claim 9 wherein the concentration of polyethylene glycol is 0.05 to 2 mg/mL, and the concentration of carboxymethyl cellulose or a salt thereof is 0.5 to 50 mg/mL.

11. The composition according to any one of claims 7 to 10 wherein the poorly soluble drug has a mean secondary particle diameter that is up to but not exceeding three times the mean primary particle diameter thereof.

12. The composition according to any one of claims 7 to 11 wherein K value of polyvinylpyrrolidone is 12 to 30.

13. The composition according to any one of claims 7 to 12 which has a viscosity of 40 Pa·s or more in at least one point in the shear rate range of 0.01 to 0.02 s^{-1} and which has a viscosity of 0.2 Pa·s or less in at least one point in the shear rate range of 900 to 1,000 s^{-1}, as measured by a rheometer at 5℃, 25℃ or 40℃.

14. The composition according to any one of claims 7 to 12 which has a viscosity of 40 Pa·s or more in at least one point in the shear rate range of 0.01 to 0.02 s^{-1} and which has a viscosity of 0.2 Pa·s or less in at least one point in the shear rate range of 900 to 1,000 s^{-1}, as measured by a rheometer at 25℃.

15. A sustained release injectable preparation comprising a composition comprising

a poorly soluble drug which is aripiprazole or a salt thereof, or 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof,

water, and

suspending agent,

wherein the suspending agent contains polyvinylpyrrolidone, and

the poorly soluble drug has a mean primary particle diameter of 1 to 10 μm and is contained in a concentration of 200 to 400 mg/mL,

the concentration of polyvinylpyrrolidone is 0.1 to 100 mg/mL,

the composition being in the form of a gel when allowed to stand, and changing to a sol when subjected to an impact, and

the preparation being administered once per month.

16. The injectable preparation according to claim 15 wherein the poorly soluble drug has a mean primary particle diameter of 2 to 7 μm.

17. A sustained release injectable preparation comprising a composition comprising

a poorly soluble drug which is aripiprazole or a salt thereof, or 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof,

water, and

suspending agent,

wherein the suspending agent contains polyvinylpyrrolidone, and

the poorly soluble drug has a mean primary particle diameter of 4 to 30 μm and is contained in a concentration of 300 to 600 mg/mL,

the concentration of polyvinylpyrrolidone is 0.1 to 100 mg/mL,

the composition being in the form of a gel when allowed to stand, and changing to a sol when subjected to an impact, and

the preparation being administered once every two to three months.

18. The injectable preparation according to claim 17 wherein the poorly soluble drug has a mean primary particle diameter of 5 to 20 μm.

19. The injectable preparation according to any one of claims 15 to 18 wherein the suspending agent further contains polyethylene glycol.

20. The injectable preparation according to any one of claims 15 to 18 wherein the suspending agent further contains polyethylene glycol and carboxymethyl cellulose or a salt thereof.

21. The injectable preparation according to claim 20 wherein the concentration of polyethylene glycol is 0.05 to 2 mg/mL, and the concentration of carboxymethyl cellulose or a salt thereof is 0.5 to 50 mg/mL.

22. The injectable preparation according to any one of claims 15 to 21 wherein K value of polyvinylpyrrolidone is 12 to 30.

23. The injectable preparation according to any one of claims 15 to 22 wherein the poorly soluble drug has a mean secondary particle diameter that is up to but not exceeding three times the mean primary particle diameter thereof.

24. The injectable preparation according to any one of claims 15 to 23 wherein the composition has a viscosity of 40 Pa·s or more in at least one point in the shear rate range of 0.01 to 0.02 s^{-1} and has a viscosity of 0.2 Pa·s or less in at least one point in the shear rate range of 900 to 1,000 s^{-1}, as measured by a rheometer at 5℃, 25℃ or 40℃.

25. The injectable preparation according to any one of claims 15 to 23 wherein the composition has a viscosity of 40 Pa·s or more in at least one point in the shear rate range of 0.01 to

0.02 s^{-1} and has a viscosity of 0.2 Pa·s or less in at least one point in the shear rate range of 900 to 1,000 s^{-1}, as measured by a rheometer at 25°C.

26. A method for treating or preventing a recurrence of schizophrenia, bipolar disorder, or depression, the method comprising administering the injectable preparation according to any one of claims 1 to 6 and 15 to 25.

27. The method according to claim 26 wherein the injectable preparation is administered intramuscularly or subcutaneously.